These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22829765)

  • 21. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A humoral immunity survey following the 2012 influenza season after the pH1N1 pandemic in Guangzhou, China.
    Huang P; Liang LJ; Huang ZZ; Zhang X; Yu SY; Su WZ; Ou CQ; Fang L; Cao DL; Zhang YH; Ke CW
    Viral Immunol; 2014 Apr; 27(3):124-8. PubMed ID: 24702517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Titration of individual strains in trivalent live-attenuated influenza vaccine without neutralization.
    Sirinonthanawech N; Surichan S; Namsai A; Puthavathana P; Auewarakul P; Kongchanagul A
    J Virol Methods; 2016 Nov; 237():154-158. PubMed ID: 27596269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine.
    Qiu C; Huang Y; Wang Q; Tian D; Zhang W; Hu Y; Yuan Z; Zhang X; Xu J
    Clin Infect Dis; 2012 Jan; 54(1):17-24. PubMed ID: 22052887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People.
    Camilloni B; Basileo M; Menculini G; Tozzi P; Iorio AM
    Adv Exp Med Biol; 2016; 897():45-53. PubMed ID: 26577530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigenic Change in Human Influenza A(H2N2) Viruses Detected by Using Human Plasma from Aged and Younger Adult Individuals.
    Matsuzawa Y; Iwatsuki-Horimoto K; Nishimoto Y; Abe Y; Fukuyama S; Hamabata T; Okuda M; Go Y; Watanabe T; Imai M; Arai Y; Fouchier RAM; Yamayoshi S; Kawaoka Y
    Viruses; 2019 Oct; 11(11):. PubMed ID: 31652870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Characterization of epidemic influenza virus A(H3N2) strains circulating in Russia in the 2003-2004 epidemic season].
    Ivanova VT; Burtseva EI; Slepushkin AN; Shchelkanov MIu; Zagorskaia IuV; Shevchenko ES; Rakutina RO; Cherkasov EG; Isaeva EI; Oskerko TA; Feodoritova EL; Maslov DV; Gatich RZ
    Vopr Virusol; 2006; 51(1):19-23. PubMed ID: 16515037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between Hemagglutinin Stem-Reactive Antibodies and Influenza A/H1N1 Virus Infection during the 2009 Pandemic.
    Hoa LNM; Mai LQ; Bryant JE; Thai PQ; Hang NLK; Yen NTT; Duong TN; Thoang DD; Horby P; Werheim HFL; Fox A
    J Virol; 2016 Jul; 90(14):6549-6556. PubMed ID: 27170747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 31. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.
    de Jong JC; Beyer WE; Palache AM; Rimmelzwaan GF; Osterhaus AD
    J Med Virol; 2000 May; 61(1):94-9. PubMed ID: 10745239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population.
    Chi CY; Liu CC; Lin CC; Wang HC; Cheng YT; Chang CM; Wang JR
    Clin Vaccine Immunol; 2010 Dec; 17(12):1958-62. PubMed ID: 20876823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age.
    Skowronski DM; Hottes TS; McElhaney JE; Janjua NZ; Sabaiduc S; Chan T; Gentleman B; Purych D; Gardy J; Patrick DM; Brunham RC; De Serres G; Petric M
    J Infect Dis; 2011 Jan; 203(2):158-67. PubMed ID: 21288814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus.
    Lemaitre M; Leruez-Ville M; De Lamballerie XN; Salez N; Garrone P; Fluckiger AC; Klatzmann D; Carrat F
    Clin Microbiol Infect; 2011 May; 17(5):732-7. PubMed ID: 20731679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Immune Priming, Vaccination, and Infection on Influenza A(H3N2) Antibody Landscapes in Children.
    Hinojosa M; Shepard SS; Chung JR; King JP; McLean HQ; Flannery B; Belongia EA; Levine MZ
    J Infect Dis; 2021 Aug; 224(3):469-480. PubMed ID: 33090202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody landscapes after influenza virus infection or vaccination.
    Fonville JM; Wilks SH; James SL; Fox A; Ventresca M; Aban M; Xue L; Jones TC; Le NMH; Pham QT; Tran ND; Wong Y; Mosterin A; Katzelnick LC; Labonte D; Le TT; van der Net G; Skepner E; Russell CA; Kaplan TD; Rimmelzwaan GF; Masurel N; de Jong JC; Palache A; Beyer WEP; Le QM; Nguyen TH; Wertheim HFL; Hurt AC; Osterhaus ADME; Barr IG; Fouchier RAM; Horby PW; Smith DJ
    Science; 2014 Nov; 346(6212):996-1000. PubMed ID: 25414313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
    Loebermann M; Voss U; Meyer S; Bosse D; Fritzsche C; Klammt S; Frimmel S; Riebold D; Reisinger EC
    PLoS One; 2013; 8(8):e70866. PubMed ID: 23976960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
    Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
    Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.
    Liu X; Liu Y; Zhang Y; Chen Z; Tang Z; Xu Q; Wang Y; Zhao P; Qi Z
    PLoS One; 2013; 8(3):e58810. PubMed ID: 23527030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigenic Maps of Influenza A(H3N2) Produced With Human Antisera Obtained After Primary Infection.
    Fonville JM; Fraaij PL; de Mutsert G; Wilks SH; van Beek R; Fouchier RA; Rimmelzwaan GF
    J Infect Dis; 2016 Jan; 213(1):31-8. PubMed ID: 26142433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.